Adma Biologics, Inc.
ADMA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001368514
No open-market purchases or sales by Adma Biologics, Inc. insiders were filed in the last 90 days; 322 institutions reported holding it in 13F filings for Q2 2026, worth $1.70B in total; superinvestors Duquesne Family Office and Fundsmith hold it.
Q1 2022 vs. Q4 2021
How the institutions holding Adma Biologics, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 88 | 105 | +17 |
| Shares | 97.2M | 104.9M | +7.67M (+7.9%) |
| Value | $137.1M | $189.9M | +$52.8M (+38.6%) |
New holders (26)
Institutions that held Adma Biologics, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
Sold out (9)
Institutions that held Adma Biologics, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Group One Trading, L.P. | 430,548 | $607.0K |
| Gsa Capital Partners LLP | 96,578 | $136.0K |
| Virtu Financial LLC | 88,315 | $125.0K |
| SG3 Management, LLC | 74,000 | $104.0K |
| Cutler Group LP | 29,522 | $41.0K |
| State of Wyoming | 11,679 | $16.0K |
| Focused Wealth Management, Inc | 100 | $0 |
| Cornerstone Advisory, LLC | 50 | $0 |
| Rinkey Investments | 100 | $0 |